Comparative Pharmacology
Head-to-head clinical analysis: SULFABID versus SULFAIR 15.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFABID versus SULFAIR 15.
SULFABID vs SULFAIR-15
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate and thereby inhibiting bacterial folate synthesis.
Sulfadoxine is a long-acting sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. Pyrimethamine inhibits dihydrofolate reductase, synergistically inhibiting nucleic acid synthesis in Plasmodium species.
500 mg orally every 12 hours for 10-14 days.
15 mg orally every 6 hours, not to exceed 60 mg/day.
None Documented
None Documented
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
12–15 hours in healthy adults; prolonged to 20–30 hours in moderate hepatic impairment.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary: 5-10% as metabolites. Fecal: <5%.
Renal excretion unchanged: 70%; hepatic metabolism to inactive metabolites: 20%; fecal excretion: 10%.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)